Pliant Therapeutics (NASDAQ:PLRX) Vs. AGIO, SUPN, SAVA, TVTX, PRTA, MORF, ISEE, DVAX, ZGNX, and BCYC
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Agios Pharmaceuticals (AGIO), Supernus Pharmaceuticals (SUPN), Cassava Sciences (SAVA), Travere Therapeutics (TVTX), Prothena (PRTA), Morphic (MORF), IVERIC bio (ISEE), Dynavax Technologies (DVAX), Zogenix (ZGNX), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical preparations" industry.
Pliant Therapeutics vs.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
99.6% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Pliant Therapeutics shares are owned by institutional investors. 8.0% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Supernus Pharmaceuticals presently has a consensus price target of $39.50, indicating a potential upside of 28.62%. Pliant Therapeutics has a consensus price target of $46.17, indicating a potential upside of 301.10%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Supernus Pharmaceuticals.
Supernus Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
In the previous week, Supernus Pharmaceuticals had 8 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 0 mentions for Pliant Therapeutics. Supernus Pharmaceuticals' average media sentiment score of 0.13 beat Pliant Therapeutics' score of -0.30 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.
Supernus Pharmaceuticals received 428 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Pliant Therapeutics an outperform vote while only 74.46% of users gave Supernus Pharmaceuticals an outperform vote.
Supernus Pharmaceuticals has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Supernus Pharmaceuticals has a net margin of 14.49% compared to Pliant Therapeutics' net margin of -914.12%. Supernus Pharmaceuticals' return on equity of 10.56% beat Pliant Therapeutics' return on equity.
Summary
Supernus Pharmaceuticals beats Pliant Therapeutics on 13 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics (NASDAQ:PLRX) vs. Its Competitors
Pliant Therapeutics Competitors List
